Prognostically, high levels of both PLOD2 (p = 0.015, Fig. 7F) and DCLK1-L (p = 0.00031, Fig. 7G) predicted poorer disease-free survival (DFS) in the TCGA ccRCC cohort. This evidence concerns the gene DCLK1 and nonpapillary renal cell carcinoma.